EMPAPRO L 25/5 TAB

About

EMPAPRO L 25/5 combines empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, with linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, providing a dual-action therapy for adults with type 2 diabetes. Empagliflozin reduces blood glucose by inhibiting the SGLT2 protein in the kidneys, which leads to increased urinary glucose excretion. This mechanism is independent of insulin secretion and helps to lower elevated blood sugar levels.

Linagliptin works by inhibiting the enzyme DPP-4, which is responsible for the rapid degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving these hormones, linagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells. The complementary actions of empagliflozin and linagliptin offer a comprehensive strategy to improve glycemic control, addressing both renal glucose handling and pancreatic hormone regulation.

Uses

• Treatment of type 2 diabetes mellitus in adults.
• To improve glycemic control as an adjunct to diet and exercise.
• For patients inadequately controlled on empagliflozin or linagliptin alone.
• To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease (due to empagliflozin).

Directions For Use

Take one tablet orally once daily, with or without food, as prescribed by your healthcare provider. Swallow the tablet whole.

Benefits

• Comprehensive blood glucose reduction.
• Improved pancreatic beta-cell function.
• Reduced risk of cardiovascular events (from empagliflozin).
• Potential for modest weight management.
• Lowered HbA1c levels.
• Convenient once-daily dosing.

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Nasopharyngitis (common cold symptoms)
• Diarrhea
• Headache
• Hypoglycemia (especially with sulfonylureas or insulin)
• Pancreatitis (rare, with DPP-4 inhibitors)
• Joint pain (arthralgia)
• Rash or skin reactions
• Dehydration
• Ketoacidosis (rare, with SGLT2 inhibitors)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake can affect blood sugar levels and hydration.
• Pregnancy - Not recommended during pregnancy due to potential risks to the fetus. Consult a doctor for alternatives.
• Breastfeeding - Avoid during breastfeeding as components may be excreted in breast milk. Seek medical advice.
• Liver - Use with caution in patients with severe hepatic impairment. No dose adjustment for linagliptin is typically needed for liver impairment.
• Kidney - No dose adjustment for linagliptin is required for renal impairment. Empagliflozin is not recommended for eGFR <30 mL/min/1.73m².
• Lung - No specific contraindications related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.